The Swiss biotech company Inofea AG founded Perseo pharma AG as spin-off for therapeutic applications. Its objective is to develop a new line of therapeutic enzymes based on Inofea’s innovative, unique and patent protected enzyme shielding technology. Foundational R&D work for such therapeutic enzymes has been successfully conducted within Inofea for two years.
Perseo pharma secured first financial resources through a convertible loan from Swiss business angels and is currently looking for further financing through a seed round.
Perseo pharma is initially focusing exclusively on therapeutic enzymes for the treatment of cancer and rare genetic diseases. However, its platform enables future enzyme-based applications in other therapeutic fields as well.
The uniqueness of empowered enzymes is the protective layer surrounding immobilized enzymes, which increases their stability and makes them resistant to harsh environments.
The technology of Inofea and Perseo pharma has been developed originally by the School of Life Sciences, University of Applied Sciences and Arts, North-Western Switzerland (FHNW).
Dr. Yves Dudal, formerly CEO of Inofea, was appointed CEO of Perseo pharma and Dr. Anne Timm, formerly CBO of Inofea, new CEO of Inofea.